Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 3 29Phase 4 6Phase EARLY_PHASE1 4Phase 1 4Phase 1/2 3

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1

Conditions

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Bone Neoplasms 1Bone Metastasis From Solid Tumors 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Denosumab × Clear all
NCT06513624 2025-07-25

ETC-159-02

National University Hospital, Singapore

Phase 1 Recruiting
16 enrolled
Gynecologic

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

NCT04798326 2021-03-15

MW032

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1 Completed
120 enrolled
Sarcoma

Bone Neoplasms

NCT01624766 2021-02-25

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

M.D. Anderson Cancer Center

Phase 1 Completed
57 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04494373 2020-08-04

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
154 enrolled
Other solid neoplasm

Bone Metastasis From Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡